Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 6

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 6
---
% or more of any of the issuer’s operating
revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent
fiscal year is accounted for by mainland China companies; and (ii) the main parts of the issuer’s business activities are
conducted in mainland China, or its main place(s) of business are located in mainland China, or the majority of senior management
staff in charge of its business operations and management are PRC citizens or have their usual place(s) of residence located in
mainland China. Subject to final determination by the CSRC and relevant competent authorities, Han Kun Law Offices, our PRC
counsel, has advised us that, based on the facts that (i) we do not operate any entities in mainland China and the revenue, total
profit, total assets or net assets as documented in our audited consolidated financial statements for the most recent fiscal year is
accounted for by our Hong Kong subsidiary located outside mainland China; (ii) except for the operation of our virtual flagship
store on Tmall Global, an e-commerce platform for international businesses to directly sell our brand-name goods to consumers in
mainland China, which was recently set up in June 2024 and has not generated sales to consumers in mainland China, as of the date of
this prospectus, our business operations are conducted in Hong Kong; and (iii) our senior management team are not PRC citizens and
have their residence located outside mainland China, we do not meet the criteria as set forth in Article 15 of the Overseas
Listing Trial Measures, and are not required to fulfill the filing procedures with the CSRC to list our securities on a U.S.
securities exchange or issue securities to foreign investors. However, as the Overseas Listing Trial Measures were newly published,
there are substantial uncertainties that the CSRC may take a view that is contrary to our understanding of the Overseas Listing
Trial Measures because the CSRC may have substantial discretion over the determination of “indirect overseas offering and
listing by a domestic company.” Han Kun Law Offices LLP, our Hong Kong counsel, has advised us that, as of the date of this
prospectus, Living Homeopathy is not required to obtain any permission or approval from the governmental authorities of Hong Kong to
list on the U.S. exchanges and offer securities.

Nevertheless, if we (i) do not receive or maintain such permissions or approvals, should such permissions or approvals be required